RBC Capital Reiterates Outperform on Corbus Pharmaceuticals, Maintains $82 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its 'Outperform' rating for Corbus Pharmaceuticals, maintaining a price target of $82.
September 20, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating for Corbus Pharmaceuticals, maintaining a price target of $82, indicating confidence in the company's future performance.
The reiteration of an 'Outperform' rating and a high price target by RBC Capital suggests positive sentiment and confidence in Corbus Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100